期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

丙种球蛋白无反应性川崎病危险因素及治疗进展 被引量：8

Novel risk factors and treatment advances of intravenous immunoglobulin unresponsiveness in children with Kawasaki disease
原文传递
导出
摘要 川崎病为累及冠状动脉在内的全身中小血管炎症,现已成为发展中国家儿童获得性心脏病的最主要病因.经标准治疗后,冠状动脉病变的发生率明显降低,但其中仍有10％～20％川崎病患儿对首剂丙种球蛋白无反应.该文对丙种球蛋白无反应性川崎病的危险因素及近几年治疗进展进行综述. Kawasaki disease is a systemic inflammation of small and middle vessels, especially coronary artery, which is the main cause of acquired heart disease in children in developing countries. Although the rate of coronary artery damage has been reduced significantly after standard treatment,there are 10% ~ 20% cases with no responsiveness to the first dose of intravenous immunoglobulin. This article reviews novel risk factors and treatment advances of intravenous immunoglobulin unresponsiveness in children with Kawasaki disease.
作者 杨敏 钟家蓉
机构地区 重庆医科大学附属儿童医院心内科、教育部儿科学国家重点学科
出处 《国际儿科学杂志》 2014年第3期256-259,共4页 International Journal of Pediatrics
关键词 川崎病 危险因素 治疗 Kawasaki disease Risk factor Treatment
分类号 R725.4 [医药卫生—儿科]
  • 相关文献

参考文献47

  • 1Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [ in Japanese ] [J]. Arerugi, 1967,16 (3) : 178-222.
  • 2Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endo- carditis an Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [ J ]. Pediatrics, 2004, 114 (6) :1708-1733.
  • 3Egami K, Muta H, Ishii M, et al. Predication of resistance to intrave- nous immunoglobulin treatment in patients with Kawasaki disease [J]. J Pediatr,2006,149(2) :237-240.
  • 4Kobayashi T, Inoue Y, Takeuchi, et al. Predication of intravenous im- munoglobulin unresponsiveness in patients with Kawasaki disease [J]. Circulation ,2006,113 ( 22 ) :2606-2612.
  • 5Sano T, Kurotobi S, Matsuzaki K, et al. Predication of non-respon- siveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment [ J]. Eur J Pediatr,2007,116 (2) :131-137.
  • 6Sleeper LA, Minich LL, McCrindie BM, et al. Evaluation of Kawasa- ki disease risk scoring system for intravenous immunoglobulin resist- ance[ J]. J Pediatr,2011,158 (5) :831-835.
  • 7Nakamura Y, Yshiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan : result of the 2007-2008 nationwide survey[ J ]. J Epidemiol,2010,20 (4) : 302 -307.
  • 8Uehara R, Belay ED, Maddox RA, et al. A analysis of potential risk factors associated with nonresponse to initial intravenous immuno- globulin treatment among Kawasaki disease patients in Japan[ J]. Pe-diatr infect Dis J,2008,27 ( 2 ) : 155-160.
  • 9Fukunishi M, Kikkawa M, Hamana K, et al. Predication of non-re- sponsiveness to intravenous high-dose gamma-globulin therapy in pa- tients with Kawasaki disease at onset [ J ]. J Pediatr, 2000,137 ( 2 ) : 172-176.
  • 10Seki M, Kobayashi T, Kobayashi T, et al. External validation of risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease[ J ]. Pediatr infect Dis J,2011,30 (2) : 145-147.

二级参考文献80

  • 1Wallace CA,French JW,Kahn SJ,Sherry DD.Initial intravenousgammaglobulin treatment failure in Kawasaki disease[J].Pediat-rics,2000,105(6):E78.
  • 2Kazatchkine MD,Kaveri SV.Immunomodulation of autoimmuneand inflammatory diseases with intravenous immune globulin[J].NEngl Med,2001,345(10):747-755.
  • 3Abe J,Jibiki T,Noma S,Nakajima T,Saito H,Terai M.Geneexpression profiling of the effect of high-dose intravenous Ig in pa-tients with Kawasaki disease[J].J Immunol,2005,174(9):5837-5845.
  • 4Taniuchi S,Masuda M,Teraguchi M,Ikemoto Y,Komiyama Y,Takahashi H,et al.Polymorphism of fcgamma riia may affect theefficacy of gamma-globulin therapy in Kawasaki disease[J].ClinImmunol,2005,25(4):309-313.
  • 5Biezeveld M,Geissler J,Merkus M,Kuipers IM,Ottenkamp J,Kuijpers T.The involvement of fc gamma receptor gene polymor-phisms in kawasaki disease[J].Clin Exp Immunol,2006,147(1):106-111.
  • 6Khor CC,Davila S,Breunis WB,Lee YC,Shimizu C,WrightVJ,et al.Genome-wide association study identifies FCGR2A as asusceptibility locus for Kawasaki disease[J].Nat Genet,2011,43(12):1241-1246.
  • 7Lee YC,Kuo HC,Chang JS,Chang LY,Huang LM,Chen MR,et al.Two new susceptibility loci for Kawasaki disease identifiedthrough genome-wide association analysis[J].Nat Genet,2012,44(5):522-525.
  • 8Onouchi Y,Ozaki K,Burns JC,Shimizu C,Terai M,Hamada第15卷第3期2013年3月中国当代儿科杂志Chin J Contemp PediatrVol.15 No.3Mar.2013H,et al.A genome-wide association study identifies three newrisk loci for Kawasaki disease[J].Nat Genet,2012,44(5):517-521.
  • 9Shrestha S,Wiener H,Shendre A,Kaslow RA,Wu J,Olson A,et al.Role of activating FcγR gene polymorphisms in Kawasaki dis-ease susceptibility and intravenous immunoglobulin response[J].Circ Cardiovasc Genet,2012,5(3):309-316.
  • 10Newburger JW,Takahashi M,Gerber MA,Gewitz MH,Tani LY,Burns JC,et al.Diagnosis,treatment,and long-term managementof Kawasaki disease:a statement for health professionals from theCommittee on Rheumatic Fever,Endocarditis,and Kawasaki Dis-ease,Council on Cardiovascular Disease in the Young.AmericanHeart Association[J].Pediatrics,2004,114(6):1708-1733.

共引文献30

同被引文献97

  • 1孙东明,王宏伟,施虹,程佩萱,常青,邓又斌.川崎病恢复期血管内皮功能障碍及相关因素分析[J].临床儿科杂志,2005,23(2):112-114. 被引量：7
  • 2张清友,杜军保.不完全川崎病的诊治现状[J].中华儿科杂志,2006,44(5):339-341. 被引量：149
  • 3杜忠东,张永兰,赵地,杜军保,鲁珊,衣京梅,侯安存,周忠蜀,丁国芳,林瑶,刘冲,北京小儿川崎病流行病学调查协作组.静脉丙种球蛋白无反应性川崎病的治疗及危险因素分析[J].中国实用儿科杂志,2006,21(10):738-741. 被引量：89
  • 4Takahashi K, Oharaseki T, Yokouchi Y. Update on etio and immuno- pathogenesis of Kawasaki disease[ J]. Curr Opin Rheumatol,2014,26(1) :31 -36.
  • 5Luca N J, Yeung RS. Epidemiology and management of Kawasaki disease [J]. Drugs,2012,72( 8 ) : 1029 - 1038.
  • 6Yim D, Curtis N, Cheung M, et al. Update on Kawasaki disease : epide- miology, aetiology and pathogenesis [J]. J Paediatr Child Health,2013, 49(9) :704-708.
  • 7Castellani ML, Anogeianaki A, Felaco P, et al. IL-35, an anti-inflamma- tory cytokine which expands CD4 + CD25+ Treg cells [J]. J Biol Regul Homeost Agents,2010,24(2) :131 - 135.
  • 8Shen P, Roeh T, Lampropoulou V, et al. IL-35-producing B cells are cri- tical regulators of immunity during autoimmune and infectious diseases [J]. Nature,2014,507 ( 7492 ) : 366 - 370.
  • 9Hu Y,Dong C ,Yue Y,et al. in vivo delivery of interleukin-35 relieves eoxsaekievLrus-B3-indueed viral myocarditis by inhibiting Th17 cells [J]. Arch Virol,2014,159(9) :2411 -2419.
  • 10Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulato- ry B cells that suppress autoimmune disease [J]. Nat Med, 2014,20 (6) :633 -641.

引证文献8

二级引证文献53

国际儿科学杂志
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部